Skip to content

tDCS Intervention on Motivational Anhedonia of Major Depressive Disorder

Study of tDCS Intervention on Motivational Anhedonia of Major Depressive Disorder

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04425278
Enrollment
90
Registered
2020-06-11
Start date
2018-03-01
Completion date
2021-12-31
Last updated
2020-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Event-Related Potentials, Major Depressive Disorder, Transcranial Direct Current Stimulation

Brief summary

Study of tDCS intervention on motivational anhedonia of Major Depressive Disorder

Detailed description

All patients underwent a medical evaluation that included physical examination and routine laboratory studies before and after transcranial direct current stimulation (tDCS) treatment. Patients were randomly allocated to real group , sham group or control group. A threshold of 3 points on the Hamilton Depression scale has been specified by the National Institute for Health and Care Excellence to determine a clinically meaningful difference between active pharmacotherapy and placebo. We plan to enroll minimum total sample size of 37 participants in real, sham or control group respectively according to the Power and Sample Size program. The decision to enroll a patient was always made prior to randomization. The tDCS administrators had access to the randomization list. They had minimal contact with the patients, and no role in assessing depression. Each patient would be treated for continuous 14 days by tDCS in real and sham group. The control group was evaluated by clinical symptom scale, behavioral evaluation before and after 14 days. Before the tDCS treatment, depression symptom of each participant was assessed by the Hamilton Depression Scale and the Beck Depression Self-Rating Scale. The anhedonia severity was evaluated by The Temporal Experience of Pleasure Scale, the Self-Report Apathy Evaluation Scale, Dimensional Anhedonia Rating Scale, the Motivation and Pleasure Scale.The neuroimaging data was collected using event-related potentials during monetary incentive delay task. After the last treatment, the same scales and neuroimaging scan were used again to assess the treatment effect of the tDCS and the underlying brain mechanism. Each participant was interviewed in detail about the adverse event of the tDCS intervention during the past 14 days.Every participant should take part in the study in voluntary and sign an informed consent form before the study.

Interventions

DEVICEtranscranial direct current stimulation with real current

transcranial direct current stimulation with real current is a noninvasive technique to activate and modify the activity of the neurons

DEVICEtranscranial direct current stimulation with sham current

transcranial direct current stimulation with sham current is a placebo

Sponsors

Anhui Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Meet criteria of depression assessed by at least two psychiatrists according to the five version of Diagnostic and Statistical Manual of Mental Disorders. 2. The score of Hamilton Depression Rating Scale-17 was larger than 18. 3. Patients were taking antidepressants--Selective Serotonin Reuptake Inhibitor(SSRIs) alone. 4. Age was between 18 to 60 year old. 5. The education duration was at least 6 years. 6. The vision or corrected vision was normal. 7. Right handedness. 8. No treatment of rTMS, transcranial direct current stimulation or electroconvulsive therapy before.

Exclusion criteria

1. History of significant head trauma or neurological disorders. 2. Alcohol or drug abuse. 3. Focal brain lesions. 4. History of seizure. 5. First degree relative with epilepsy, significant neurological illness or head trauma, endocrine disease. 6. Significant unstable medical condition. 7. Recent aggression or other forms of behavioral dyscontrol. 8. Left-handedness. 9. Pregnancy. 10. Current alcohol or drug abuse 11. Inability to provide informed consent. 12. Patients with contraindications or factors affecting imaging quality, such as pacemakers, cochlear implants, or hearts Cerebrovascular metal stent, and metal denture.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in Hamilton Depression Scalebaseline;14 day post-treatmentThe participants' depression symptom assessed by the Hamilton Depression Scale change from baseline after the treatment.
Change from baseline in Motivation and Pleasure Scalebaseline;14 day post-treatmentThe severity of participants' anhedonia assessed by the Motivation and Pleasure Scale change from baseline after the treatment.

Secondary

MeasureTime frameDescription
The change from baseline in behavioral results of Monetary Incentive Delay taskbaseline; 14 day post-treatment change from baseline after the treatment.The motivational anhedonia assessed by accuracy and response time in Monetary Incentive Delay task
The change from baseline in event-related brain potentials during the monetary incentive delay taskbaseline; 14 day post-treatmentThe amplitudes of brain potentials of contingent negative variation and P3 assessed by event-related brain potentials methods change from baseline after the treatment.

Countries

China

Contacts

Primary ContactFengqiong Yu, MD
yufengqin1@163.com0086055115955155423

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026